Missing Supplementary Information
In the original article, there was a mistake in the published supplementary material. The literature search string as mentioned in the section “Literature Search and Selection Strategy” never appeared in the published material. The search string as applied in Medline appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.
Ovid Technologies, Inc. Email Service
Database: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)<1946 to Present>
Search Strategy:
1 Hyperparathyroidism, Primary/dt [Drug Therapy] (99)
2 Hyperparathyroidism, Primary/(2211)
3 Parathyroid adenom*.mp. (4188)
4 (Primary adj2 Hyperparathyr*).mp. (9043)
5 2 or 3 or 4 (11256)
6 exp Diphosphonates/(22931)
7 bisphosphonate*.mp. (14211)
8 diphosphonat*.mp. (17321)
9 bisphosphonic*.mp. (152)
10 clodron*.mp. (2326)
11 alendron*.mp. (4714)
12 etidron*.mp. (3123)
13 ibandron*.mp. (1063)
14 incadron*.mp. (78)
15 medron*.mp. (4405)
16 minodron*.mp. (104)
17 neridron*.mp. (94)
18 olpadron*.mp. (77)
19 pamidron*.mp. (2920)
20 risedron*.mp. (1775)
21 tiludron*.mp. (156)
22 zoledron*.mp. (4145)
23 cinacalcet.mp. (1071)
24 Cinacalcet Hydrochloride/(735)
25 "amg 073".mp. (24)
26 amg073.mp. (0)
27 krn 1493.mp. (3)
28 krn1493.mp. (4)
29 mimpara.mp. (20)
30 parareg.mp. (0)
31 regpara.mp. (1)
32 sensipar.mp. (30)
33 exp Isoflavones/(15928)
34 ipriflavone.mp. (268)
35 Denosumab/(925)
36 denosumab.mp. (1712)
37 amg 162.mp. (33)
38 amg162.mp. (3)
39 amgiva.mp. (0)
40 prolia.mp. (32)
41 xgeva.mp. (16)
42 blosozumab.mp. (14)
43 ly 2541546.mp. (0)
44 ly2541546.mp. (1)
45 romosozumab.mp. (45)
46 amg 785.mp. (27)
47 amg785.mp. (0)
48 cdp 7851.mp. (0)
49 cdp7851.mp. (3)
50 odanacatib.mp. (156)
51 ("mk 0822" or mk0822 or mk822 or mk 822).mp. (5)
52 etelcalcetide.mp. (5)
53 (amg 416 or amg416).mp. (12)
54 (kai 4169 or kai4169).mp. (1)
55 (ono 5163 or ono5163).mp. (0)
56 telcalcetide.mp. (0)
57 velcalcetide.mp. (4)
58 or/6-57 (49081)
59 5 and 58 (459)
60 1 or 59 (491)
Statements
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
primary hyperparathyroidism, parathyroid adenoma, medical treatment, drug therapy, bisphosphonates, cinacalcet
Citation
Leere JS, Karmisholt J, Robaczyk M and Vestergaard P (2017) Corrigendum: Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review. Front. Endocrinol. 8:172. doi: 10.3389/fendo.2017.00172
Received
30 June 2017
Accepted
04 July 2017
Published
20 July 2017
Volume
8 - 2017
Edited and reviewed by
Patrizia D’Amelio, University of Turin, Italy
Updates
Copyright
© 2017 Leere, Karmisholt, Robaczyk and Vestergaard.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Julius Simoni Leere, j.leere@rn.dk
Specialty section: This article was submitted to Bone Research, a section of the journal Frontiers in Endocrinology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.